​

Biogen (BIIB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIIB Stock Forecast

Biogen (BIIB) stock forecast, based on 43 Wall Street analysts, predicts a 12-month average price target of $229.27, with a high of $315.00 and a low of $118.00. This represents a 90.79% increase from the last price of $120.17.

$100 $150 $200 $250 $300 $350 High: $315 Avg: $229.27 Low: $118 Last Closed Price: $120.17

BIIB Stock Rating

Biogen stock's rating consensus is Buy, based on 43 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 27 Buy (62.79%), 16 Hold (37.21%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 43 16 27 0 Strong Sell Sell Hold Buy Strong Buy

BIIB Price Target Upside V Benchmarks

TypeNameUpside
StockBiogen90.79%
SectorHealthcare Stocks 30.37%
IndustryDrug Manufacturers - General Stocks30.04%

Price Target Trends

1M3M12M
# Anlaysts1525
Avg Price Target$118.00$195.60$259.36
Last Closing Price$120.17$120.17$120.17
Upside/Downside-1.81%62.77%115.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2561317--36
Mar, 2561317--36
Feb, 2551316--34
Jan, 2561416--36
Dec, 2471515--37
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 28, 2025HSBC$118.00$119.12-0.94%-1.81%
Feb 13, 2025Sumant KulkarniCanaccord Genuity$265.00$138.0691.95%120.52%
Dec 09, 2024Michael YeeJefferies$180.00$157.7814.08%49.79%
Nov 15, 2024Brian SkorneyRobert W. Baird$300.00$162.8384.24%149.65%
Oct 31, 2024Jay OlsonOppenheimer$255.00$181.1840.74%112.20%
Oct 31, 2024Terence FlynnMorgan Stanley$204.00$181.1812.60%69.76%
Oct 30, 2024Christopher RaymondRaymond James$315.00$181.1873.86%162.13%
Oct 30, 2024Salveen RichterGoldman Sachs$290.00$181.1860.06%141.32%
Oct 17, 2024Evan SeigermanBMO Capital$230.00$188.1722.23%91.40%
Oct 03, 2024Ashwani VermaUBS$202.00$188.747.03%68.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 28, 2025HSBCBuyHolddowngrade
Feb 13, 2025Canaccord GenuityBuyBuyhold
Jan 02, 2025Piper SandlerOverweightNeutraldowngrade
Dec 09, 2024JefferiesBuyHolddowngrade
Nov 13, 2024CitigroupNeutralNeutralinitialise
Oct 31, 2024OppenheimerOutperformOutperformhold
Oct 31, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Oct 30, 2024Piper SandlerOverweightOverweighthold
Oct 30, 2024Goldman SachsBuyBuyhold
Oct 17, 2024BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$5 $12 $19 $26 $33 $40 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.86$10.44$20.97$8.02$11.20----
Avg Forecast$33.79$19.19$17.11$14.99$16.42$16.48$17.37$18.95$20.72
High Forecast$36.21$20.57$18.68$15.57$17.18$20.03$25.69$26.87$23.62
Low Forecast$31.69$18.00$15.76$14.74$16.13$14.45$13.83$15.13$18.61
Surprise %-26.43%-45.60%22.56%-46.50%-31.79%----

Revenue Forecast

$9B $10B $11B $12B $13B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$13.44B$10.98B$10.17B$9.84B$9.68B----
Avg Forecast$13.38B$10.87B$10.07B$9.93B$9.63B$9.43B$9.56B$9.92B$10.14B
High Forecast$14.12B$11.47B$10.78B$10.08B$9.74B$10.42B$9.57B$9.94B$11.23B
Low Forecast$12.74B$10.35B$9.46B$9.78B$9.55B$8.69B$9.56B$9.89B$9.35B
Surprise %0.48%1.01%1.00%-0.93%0.43%----

Net Income Forecast

$500M $1B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.00B$1.56B$3.05B$1.16B$1.63B----
Avg Forecast$3.27B$1.37B$1.82B$1.16B$2.42B$2.51B$2.37B$2.56B$3.02B
High Forecast$3.92B$1.64B$2.18B$1.39B$2.50B$2.92B$3.74B$3.91B$3.44B
Low Forecast$2.61B$1.09B$1.46B$928.88M$2.35B$2.10B$2.01B$2.20B$2.71B
Surprise %22.39%13.84%67.40%--32.69%----

BIIB Forecast FAQ

Is Biogen stock a buy?

Biogen stock has a consensus rating of Buy, based on 43 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 27 Buy, 16 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Biogen is a favorable investment for most analysts.

What is Biogen's price target?

Biogen's price target, set by 43 Wall Street analysts, averages $229.27 over the next 12 months. The price target range spans from $118 at the low end to $315 at the high end, suggesting a potential 90.79% change from the previous closing price of $120.17.

How does Biogen stock forecast compare to its benchmarks?

Biogen's stock forecast shows a 90.79% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the drug manufacturers - general stocks industry (30.04%).

What is the breakdown of analyst ratings for Biogen over the past three months?

  • April 2025: 16.67% Strong Buy, 36.11% Buy, 47.22% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 16.67% Strong Buy, 36.11% Buy, 47.22% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 14.71% Strong Buy, 38.24% Buy, 47.06% Hold, 0% Sell, 0% Strong Sell.

What is Biogen’s EPS forecast?

Biogen's average annual EPS forecast for its fiscal year ending in December 2025 is $16.48, marking a 47.14% increase from the reported $11.2 in 2024. Estimates for the following years are $17.37 in 2026, $18.95 in 2027, and $20.72 in 2028.

What is Biogen’s revenue forecast?

Biogen's average annual revenue forecast for its fiscal year ending in December 2025 is $9.43B, reflecting a -2.54% decrease from the reported $9.68B in 2024. The forecast for 2026 is $9.56B, followed by $9.92B for 2027, and $10.14B for 2028.

What is Biogen’s net income forecast?

Biogen's net income forecast for the fiscal year ending in December 2025 stands at $2.51B, representing an 53.80% increase from the reported $1.63B in 2024. Projections indicate $2.37B in 2026, $2.56B in 2027, and $3.02B in 2028.